openPR Logo
Press release

Pharmacy OneSource Announces Free Webinar on Software Alert Fatigue

06-08-2011 08:28 AM CET | Health & Medicine

Press release from: Pharmacy OneSource

Bellevue, Wash. – Wolters Kluwer Health announced today that Pharmacy OneSource, software-as-a-service provider of Sentri7, a clinical surveillance, documentation and reporting application, is hosting a complimentary webinar with Andrew Segar, PharmD, and John Horn, PharmD, in "Alert Fatigue with Drug-Drug Interaction Software: The Way Forward."

Seger and Horn will discuss drug-drug interaction (DDI) alerting limitations and how it fails both patients and practitioners. They will review the results of studies evaluating DDI alerts and how they are received by practitioners. In addition, they will present information that will describe potential solutions to potentially improve the quality of DDI alerting. Common approaches to the problem of alert fatigue, including limiting the categories of alerts that trigger and database customization, will be reviewed with emphasis on the advantages and limitations of each approach.

From this presentation, attendees should be able to describe how DDI alerting works from an informatics perspective and develop strategies to enhance the quality of DDI alerting locally.

Alert Fatigue with Drug-Drug Interaction Software: The Way Forward
DATE: Wednesday, June 22, 2011
TIME: 12:00 PM - 1:00 PM EST
WHERE: http://www.pharmacyonesource.com/webinars

About the Presenters: Andy Seger graduated with a BS in Pharmacy in 1984 and Doctor of Pharmacy in 2003 from the Massachusetts College of Pharmacy and Health Sciences. He is currently a Senior Research Pharmacist with Clinical Quality & Analysis, Information Systems at Partners HealthCare Systems and The Division of General Internal Medicine & Primary Care at Brigham & Women’s Hospital. In addition, he is a Senior Research Pharmacist in The Venous Thromboembolism Research Group in the Cardiovascular Division at Brigham and Women’s Hospital.

John Horn is a Professor of Pharmacy, Department of Pharmacy at the University of Washington School of Pharmacy and an Associate Director of the University of Washington Medical Center Pharmacy Services. He has authored over 175 articles related to drug interactions. He is co-author of The Top 100 Drug Interactions; A Guide to Patient Management. Horn has co-authored the reference text Hansten and Horn’s Drug Interactions Analysis and Management for over 20 years.

About Pharmacy OneSource
Pharmacy OneSource® is healthcare's #1 Software-as-a-Service (SaaS) provider. Our more than 100 innovative team members provide best-in-class, SaaS solutions to current and future challenges within health-systems worldwide. Our SaaS solutions contribute to swift and safe healthcare through earlier, easier and better access to data. More than 1,300 healthcare organizations worldwide utilize our HIPAA compliant web-based services.

Pharmacy OneSource is part of Wolters Kluwer Health, a leading global provider of information, business intelligence and point-of-care solutions for the healthcare industry. Wolters Kluwer Health is part of Wolters Kluwer, a market-leading global information services company with 2010 annual revenues of €3.6 billion ($4.7 billion).

Pharmacy OneSource
3535 Factoria Blvd. SE #440
Bellevue, WA 98006

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Pharmacy OneSource Announces Free Webinar on Software Alert Fatigue here

News-ID: 178491 • Views:

More Releases from Pharmacy OneSource

Richie's Specialty Pharmacy Selects Simplifi 797 for USP 797 Compliance
Wolters Kluwer Health, a leading global provider of information for healthcare professionals and students, announced today that Richie's Specialty Pharmacy, LLC has selected its Simplifi 797 software for achieving sterile compounding compliance. Simplifi 797 is a web-based application that automates, integrates and streamlines quality activities and documentation related to U.S. Pharmacopeia's Chapter 797 guidelines. The software manages task scheduling for environmental monitoring and automates the reporting of exceptions and compliance. "Simplifi
Pharmacy OneSource® Partners with CriticalPoint™ to Offer the Next Generation …
Bellevue, Washington – Wolters Kluwer Health, a leading global provider of information for healthcare professionals and students, announced today that Pharmacy OneSource® has released a new version of Simplifi 797®, a web-based quality assurance software for USP chapter 797 compounding compliance. The upgraded version of Simplifi 797 includes CriticalPoint's education program, which gives users unlimited access to 42 hours of ACPE-approved continuing education credits supporting compliance with USP Chapter . Lessons
Wolters Kluwer Health Unveils Integration between UpToDate and Sentri7
Bellevue, WA -- Wolters Kluwer Health, a leading global provider of information for healthcare professionals and students, announced today that UpToDate's clinical knowledge system has been integrated with Sentri7 surveillance software by Pharmacy OneSource. This partnership of evidence-based clinical information through UpToDate and clinical patient surveillance from Sentri7 offers healthcare providers actionable information at the point of care to make better decisions in directing patient care. UpToDate synthesizes the most recent medical

More Releases for Drug

Alcohol Testing And Drug Testing Equipment Market 2025 Segmentation, Application …
Market Study Report, LLC, has compiled an exhaustive research study of the ‘Alcohol Testing And Drug Testing Equipment market’, detailing every single market driver and intricately analyzing the business vertical. This ‘Alcohol Testing And Drug Testing Equipment market’ study will aid in seeking out new business opportunities and fine-tuning existing marketing strategies through insights regarding SWOT analysis, market valuation, competitive spectrum, regional share, and revenue predictions. Alcohol abuse and drug
How much Diabetes Drug Market Impact Worldwide Medical Drug Industry?
Diabetes Drug Market From an insight perspective, the market report focuses on various levels of analyses — industry analysis, market rank analysis, and company profiles, which together comprise and discuss basic views on the competitive landscape, high-growth regions, and countries as well as their respective regulatory policies, Types ,Applications and opportunities in the market.  Diabetes is a metabolic disorder in which the body glucose level is elevated. There are two types of diabetes
Hepatitis Drug Market Hepatitis Drug Clinical Pipeline Report 2023
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Introduction to Hepatitis Disease 1.1 Prologue 1.1.1 History of Hepatitis 1.1.2 Causes of Hepatitis Disease 1.2 Types of Viruses which are Responsible for Hepatitis Disease 2. Global Prevalence of Hepatitis Infection 3. Available Drug Classes for Hepatitis Disease Treatment 3.1 Interferon Alfa Therapy 3.2 Protease Inhibitors Therapy 3.3 Polymerase
Microcapsules Drug Delivery Market Microcapsules Drug Delivery Sales Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Indispensable Advent of Microcapsules 1.1 Trajectory of Microencapsulation 1.2 Why and wherefores for Microencapsulation 2. Characterization of Microcapsules 2.1 Composition of Microcapsules 2.2 Parameters Influencing Microcapsules 3. Engineering Technology of Microcapsules 3.1 Physical Manufacturing Technologies 3.2 Physicochemical and Chemical Technologies 4. Applicability of Microcapsules 4.1 Microcapsules in Pharmaceuticals 4.2 Microcapsules in Nutraceuticals
AstraZeneca’s NMOSD Drug receives orphan drug designation
April 18, 2017 Orphan Drug European Medicine Agency has Announced orphan drug designation for inebilizumab (earlier known as MEDI-551) developed by AstraZeneca PLC (AZN) for the treatment of neuromyelitis optica spectrum disorder (NMOSD). The drug has already received orphan drug status from US Food and Drug Administration (FDA). NMOSD, also called Devic’s disease, is a rare, autoimmune disorder of the central nervous system (CNS) that affects the functioning
Drug Discovery Strategies, PBPK Modeling and Drug-Drug Interaction Explored and …
This year’s 12th annual ADMET conference and exhibition promises to deliver appearances from experienced pharmaceutical professionals from ADME and PK/PD organisations such as AbbVie, GSK, Roche and Bayer when it returns to London this June. The carefully selected speaker line up will be addressing early ADME application strategies and discussing the latest technologically advanced screening and testing models along with exploring ADMET technologies which will identify properties of a drug